Twist Bioscience vs Biconomy

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (16 vs 20)
Twist Bioscience logo

Twist Bioscience

GrowthLife Sciences & BioTech

Synthetic Biology & DNA Synthesis

Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, pharma, and AgBio.

AI VisibilityBeta
Overall Score
D16
Category Rank
#1 of 1
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
20
Perplexity
10
Gemini
23

About

Twist Bioscience was founded in 2013 in San Francisco by Emily Leproust, Bill Banyai, and Bill Peck, pioneering a silicon-based DNA synthesis platform that writes synthetic DNA at a fraction of the cost and error rate of conventional methods. By printing DNA on silicon wafers using a semiconductor-like process, Twist dramatically reduced the cost of synthetic genes from hundreds to single-digit dollars per gene, democratizing access to DNA writing for the life sciences.\n\nTwist serves over 3,000 customers across biopharmaceuticals, academic research, agriculture, and industrial biotechnology, offering synthetic genes, variant libraries, DNA data storage oligos, and antibody libraries for drug discovery. The company reported $376.6 million in FY2025 revenue, up 20% from $313 million in FY2024, driven by strong growth in its biopharma and drug discovery segments. Twist also operates a growing antibody drug discovery business, providing synthetic antibody libraries that power next-generation therapeutic discovery programs.\n\nTwist has a supply agreement with Ginkgo Bioworks for synthetic DNA to fuel Ginkgo's cell engineering platform, revised in 2025. The company is executing toward profitability, with improving gross margins as manufacturing scale increases. Its silicon-based DNA synthesis platform positions it as critical infrastructure for the emerging bioeconomy, synthetic biology, and DNA data storage industries.

Full profile
Biconomy logo

Biconomy

EmergingWeb3

Web3 Transaction Infrastructure

Web3 authentication and account abstraction infrastructure enabling gasless transactions and simplified dApp onboarding; ERC-4337 implementation allows dApps to sponsor gas fees on behalf of users and accept ERC-20 token gas payment for mainstream-accessible wallet experiences.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1 of 1
AI Consensus
55%
Trend
up
Per Platform
ChatGPT
13
Perplexity
26
Gemini
13

About

Biconomy is a Web3 infrastructure platform focused on making decentralized applications usable by mainstream audiences who are not familiar with cryptocurrency gas mechanics. Its core product implements account abstraction via ERC-4337, allowing dApp developers to sponsor gas fees on behalf of users, accept gas payment in ERC-20 tokens instead of native currency, and batch multiple on-chain transactions into a single user action. These capabilities transform the user experience from one requiring native token balances and technical awareness into something closer to a conventional web application workflow.

Full profile

AI Visibility Head-to-Head

16
Overall Score
20
#1
Category Rank
#1
68
AI Consensus
55
up
Trend
up
20
ChatGPT
13
10
Perplexity
26
23
Gemini
13
17
Claude
28
13
Grok
15

Key Details

Category
Synthetic Biology & DNA Synthesis
Web3 Transaction Infrastructure
Tier
Growth
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Twist Bioscience
Synthetic Biology & DNA Synthesis
Only Biconomy
Web3 Transaction Infrastructure

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.